Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2022-05-28 Report Publication Anno…
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Newspaper Advertisements
Report Publication Announcement Classification · 95% confidence The document contains a letter dated May 28, 2022, addressed to stock exchanges (BSE Limited and National Stock Exchange of India Limited) regarding the submission of copies of published Audited Consolidated Financial Results for the quarter and year ended March 31, 2022. The letter mentions that the audited consolidated financial results have been published in newspapers on May 28, 2022. The document is about the submission and publication of the audited consolidated financial results, which is typically part of an Annual Report or Quarterly Report. However, the document itself is a letter submitting copies of the published results and does not contain the full financial statements or detailed financial analysis. It is more of an announcement or submission notice rather than the full report. The document length is 15,000 characters, but the content is primarily a submission letter and publication notice. According to the MENU VS MEAL RULE, if a document is short and states that a report is published or attached, it should be classified as a Report Publication Announcement (RPA) rather than the report itself. Therefore, this document is best classified as a Report Publication Announcement (RPA).
2022-05-28 English
General updates
Capital/Financing Update Classification · 95% confidence The document is a press release dated May 28, 2022, announcing a cooperative agreement of $149.6 million between Jubilant HollisterStier LLC (a wholly owned subsidiary of Jubilant Pharmova Limited) and the US Government for vaccine manufacturing capacity expansion. It is addressed to stock exchanges and references regulatory compliance (Regulation 30 of SEBI Listing Obligations). The content is a detailed announcement of a financing/cooperative agreement related to capital investment and expansion, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial results. The document is not a report publication announcement or a certification. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length (8441 characters) supports it being a full announcement rather than a brief notice.
2022-05-28 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter under SEBI regulations informing about the availability of an audio recording of a conference call related to the audited financial results for the quarter and financial year ended March 31, 2022. It provides a link to the recording but does not contain the transcript or detailed financial data itself. The document length is only 1256 characters, indicating it is an announcement rather than a full report or transcript. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a regulatory disclosure notice about the conference call recording, not the call transcript itself or a financial report.
2022-05-28 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed filing dated May 27, 2022, containing audited standalone and consolidated financial results for the quarter and year ended March 31, 2022. It includes an Independent Auditor's Report with an unmodified opinion, detailed financial statements including income, expenses, assets, and liabilities, and notes on accounting policies and management responsibilities. The presence of full financial data, audit opinion, and comprehensive financial disclosures indicates this is a full annual financial report. The document references compliance with Regulation 33 of the SEBI Listing Regulations, which pertains to quarterly and annual financial results disclosures in India. Given the comprehensive nature and inclusion of audited annual financial results, this filing corresponds to an Annual Report type document. It is not merely an announcement or a certification, but the full audited financial results with auditor's report. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2022-05-27 English
Dividend
Notice of Dividend Amount Classification · 100% confidence The document is a letter addressed to stock exchanges informing them about the Board of Directors' recommendation of a dividend for the fiscal year ended March 31, 2022. It mentions the dividend amount per equity share and the expected payment date, pending shareholder approval at the upcoming Annual General Meeting. The document is short (1116 characters) and serves as an official announcement of dividend details rather than a full report or financial statement. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-05-27 English
Outcome of Board Meeting
Notice of Dividend Amount Classification · 100% confidence The document is a letter addressed to stock exchanges informing them about the Board of Directors' recommendation of a dividend for the fiscal year ended March 31, 2022. It mentions the dividend amount per equity share and the expected payment date, pending shareholder approval at the upcoming Annual General Meeting. The document is short (1116 characters) and serves as an official announcement of dividend details rather than a full report or financial statement. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-05-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.